显微镜下的肺动脉高压:组织病理学对诊断和治疗的意义
本文综述肺动脉高压(PH)各亚型中肺微血管病理重塑的差异。实验模型和人类组织学研究显示,不同PH分组具有独特的动脉或静脉病理特征,这些结构差异可解释治疗反应差异,如血管扩张剂在毛细血管前小动脉病变有效但可能在静脉为主型中诱发肺水肿。整合组织病理学与血流动力学及无创评估可能有助于早期检出肺血管病并支持精准治疗。
要点
- 不同PH分组的肺微血管重塑模式不同,静脉为主型与动脉为主型对治疗反应有差异。
- 血管扩张剂在毛细血管前小动脉病变为主者有效,但在静脉为主型PH中可能诱发肺水肿。
- 慢性血栓栓塞性肺动脉高压的远端小动脉病理是治疗靶点,但静脉重塑可能解释结局异质性。
核心结论
- PH各分组间肺血管重塑差异显著,动脉和静脉特征不同,影响血流动力学、治疗反应和结局。
- 整合组织病理学与血流动力学表型及无创评估可能有助于早期检出肺血管病并支持精准治疗。
研究设计与样本
- 综述,总结实验模型(如野百合碱、缺氧)和人类组织学研究,未报告系统检索范围。
主要发现
- 实验模型揭示中膜肥厚、远端新生肌化、内膜纤维化和再通等机制,但细胞通路和血管 compartments 存在差异。
- 人类组织学研究证实这些变化并显示分组特异性特征:第2组PH以静脉重塑为主,肺静脉闭塞病为致密闭塞性静脉纤维化,第1组肺动脉高压为动脉为主病变,慢性血栓栓塞性肺动脉高压为混合动静脉改变。
- 超声心动图指标如三尖瓣环收缩期位移/右心室收缩压和运动血流动力学可能作为微血管病的生理替代标志,但与组织病理学的直接相关性仍有限。
临床怎么用
- 血管扩张剂在毛细血管前小动脉为主病变中有效,但在静脉为主型PH表型中可能诱发肺水肿。
- 慢性血栓栓塞性肺动脉高压中远端小动脉病理为治疗靶点,但静脉重塑可能影响结局异质性。
局限性
- 新兴无创标志物与组织病理学的直接相关性仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: Pulmonary hypertension (PH) comprises a heterogeneous group of conditions characterized by elevated mean pulmonary artery pressure and is classified into 5 groups according to underlying etiology. Across PH subtypes, pathologic remodeling of the pulmonary microvasculature, including arterioles, capillaries, and venules, drives hemodynamic burden, right ventricular dysfunction, and clinical outcomes. Although certain structural features are conserved, distinct histopathologic patterns shape group-specific pathophysiology, treatment responses, and prognosis. REVIEW FINDINGS: Experimental models (eg, monocrotaline, hypoxia) have revealed key mechanisms of medial hypertrophy, distal neomuscularization, intimal fibrosis, and recanalization, but also highlight differences in cellular pathways and vascular compartments involved. Human histologic studies confirm these changes and demonstrate group-specific signatures: venule-predominant remodeling in group 2 PH, dense occlusive venous fibrosis in pulmonary veno-occlusive disease, arterial-dominant lesions in group 1 pulmonary arterial hypertension, and mixed arterial-venous changes in chronic thromboembolic pulmonary hypertension. These structural differences help explain variable therapeutic responses; for example, vasodilators are effective in precapillary arteriolar predominant disease but may precipitate pulmonary edema in venous-predominant PH phenotypes. In chronic thromboembolic pulmonary hypertension, distal arteriolar pathology is a therapeutic target; however, venous remodeling may underlie heterogeneity of outcomes. Emerging noninvasive markers, including echocardiographic indices such as tricuspid annular plane systolic excursion/right ventricular systolic pressure and exercise hemodynamics, may provide physiological surrogates of microvascular disease; however, direct correlations with histopathology remain limited. SUMMARY: Pulmonary vascular remodeling varies substantially across PH groups, with distinct arterial and venous signatures that influence hemodynamics, treatment response, and outcomes. Integrating histopathologic insights with hemodynamic phenotyping and noninvasive assessments may enable earlier detection of pulmonary vascular disease and support more precise, mechanism-directed therapeutic strategies.
引用
- Dagan M, Nanayakkara S, Chan W, et al. Pulmonary Hypertension Under the Microscope: What Histopathology Means for Diagnosis and Treatment. Chest. 2026. PMID: 42521151. doi:10.1016/j.chest.2026.07.5215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。